Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13242
Abstract: Pooled efficacy studies suggest that glycaemic responses to dipeptidyl‐peptidase 4 inhibitors in type 2 diabetes are greatest in Asians, who may also respond better to alpha‐glucosidase inhibitors. We assessed the glycaemic impact of sitagliptin by… read more here.
Keywords: evaluating cardiovascular; sitagliptin tecos; cardiovascular outcomes; outcomes sitagliptin ... See more keywords
Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs.
Sign Up to like & getrecommendations! Published in 2017 at "Circulation"
DOI: 10.1161/circulationaha.117.027288
Abstract: Some drugs used to treat noncardiovascular conditions may adversely impact the cardiovascular status of individuals both with and without known cardiovascular disease. When the US Food and Drug Administration judges the potential cardiovascular safety signal… read more here.
Keywords: evaluating cardiovascular; phase; safety nonsteroidal; safety ... See more keywords
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes Care"
DOI: 10.2337/dc16-1135
Abstract: OBJECTIVE Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial assessing the impact… read more here.
Keywords: evaluating cardiovascular; trial; sitagliptin; safety ... See more keywords